ARQ Wealth Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$623K Buy
536
+20
+4% +$20.4K 0.08% 138
2026
Q1
$475K Hold
516
0.09% 134
2025
Q4
$555K Sell
516
-116
-18% -$111K 0.15% 87
2025
Q3
$482K Buy
632
+246
+64% +$183K 0.14% 92
2025
Q2
$319K Hold
386
0.11% 87
2025
Q1
$319K Buy
386
+16
+4% +$13.3K 0.12% 82
2024
Q4
$286K Sell
370
-2
-0.5% -$1.66K 0.11% 84
2024
Q3
$357K Hold
372
0.14% 73
2024
Q2
$337K Buy
372
+81
+28% +$64.8K 0.15% 70
2024
Q1
$226K Buy
+291
New +$207K 0.1% 82

Other funds holding LLY

ARQ Wealth Advisors's LLY Position: Q2 2026 in Review

ARQ Wealth Advisors increased its Eli Lilly (LLY) stake by 3.9% in Q2 2026, buying an estimated $20.4K and bringing the position to 536 shares worth $623K. The position accounts for 0.08% of the portfolio, ranked #138.

ARQ Wealth Advisors first reported a position in LLY in Q1 2024 and has held it in 10 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • ARQ Wealth Advisors held 536 shares of Eli Lilly worth $623K as of Q2 2026.
  • ARQ Wealth Advisors bought 20 Eli Lilly shares in Q2 2026, an estimated $20.4K.
  • Eli Lilly made up 0.08% of ARQ Wealth Advisors's portfolio in Q2 2026, its #138 holding.
  • ARQ Wealth Advisors first reported a position in Eli Lilly in Q1 2024 and has held it in 10 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on ARQ Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.